In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this internet live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, August 10, 2021. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via email. Your CME certificate will be sent to you via email after the completion of the activity.

Request for Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

Sarcomas are a rare group of malignant tumor types that make up about 1% of all cancers. There are approximately 13,460 new cases of soft tissue sarcomas and 3,610 new cases of bone sarcomas detected each year, and in 2021, an estimated 5,350 and 2,060 Americans will die of soft tissue sarcoma and bone sarcoma respectively.  Although rare, sarcomas are proportionally more common among children than adults, representing about 15% of pediatric cancers, after hematological malignancies and central nervous system tumors.

Sarcomas are a heterogeneous group of over 80 different tumors arising from mesenchymal or connective tissue. Sarcoma can develop from various types of soft tissues in the body, as well as bone. About 50% of sarcomas develop in an arm or leg, and 40% in the trunk or abdomen. Amongst children, the most common types of sarcomas are rhabdomyosarcomas, osteosarcomas and Ewing’s Sarcoma. Sarcomas are often painless and detect at a late stage.

The complexity and rarity of sarcomas make them challenging to study as well as medically manage. Identifying the specific origin of a sarcoma can be challenging but an understanding of the tumor type is crucial to enable selection of the best treatment approach for each patient. Efforts are being made to improve detection and classification of sarcomas using genetic analyses and biomarkers.

Treatment of patients with sarcoma is typically multimodal, involving surgery to resect the tumor if possible, as well as radiation and chemotherapy. However, 50% of sarcoma cases do not respond to conventional therapies and many relapse or recur as inoperable or metastatic tumors. The 5-year relative survival rate for both bone and soft tissue sarcoma is 65 percent, and death rates have remained unchanged over the past decade.

There is a significant need for new therapies, but this is challenging, particularly due to the small patient populations affected by each sarcoma type, and the ethical limitations on pediatric clinical trials. Promising advances in the understanding of the genetics and molecular pathology of sarcomas have recently been made, and the development of novel targeted therapies has allowed more accurate and effective, histology-driven treatment plans.

After participating in this CME activity, physicians should be able to:

  1. Evaluate the utility of novel model systems to inform clinical cancer research.
  2. Identify perturbations in signaling pathways with potential impact on the selection of therapeutic approaches. 
  3. Assess therapeutic strategies that combine genomic research with precision medicine to improve risk assessment, detection, diagnostic and treatment selection.
  4. Identify immunological contributions towards sarcoma cancer initiation, progression and treatment response.
  5. Evaluate recent clinical advances made in treating soft-tissue and bone sarcomas.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

Planner and Speaker Financial Disclosure Index

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants which will be disclosed at the meeting. Any others will be disclosed at the activity.

Questions about CME?

AACR Virtual Meeting: Sarcomas FAQ’s

Please contact the Office of CME at (215) 440-9300 or [email protected].